Company Releases Early Data and Plans to Boost Dose in Duchenne Muscular Dystrophy Trial
PhotoLizM / Pixabay

Company Releases Early Data and Plans to Boost Dose in Duchenne Muscular Dystrophy Trial

According to a story from pm360online.com, the life sciences company Solid Biosciences has released some preliminary findings from its Phase 1/2 clinical trial of SGT-001. This investigational product is in…

Continue Reading Company Releases Early Data and Plans to Boost Dose in Duchenne Muscular Dystrophy Trial
Company Plans Extension Study for Phase 3 Trial of Amyotrophic Lateral Sclerosis Drug
source: pixabay.com

Company Plans Extension Study for Phase 3 Trial of Amyotrophic Lateral Sclerosis Drug

According to a story from pm360online.com, the Orion Corporation, a pharmaceutical company based in Finland, has recently announced that it plans to continue its Phase 3 trial of levosimendan as…

Continue Reading Company Plans Extension Study for Phase 3 Trial of Amyotrophic Lateral Sclerosis Drug
Company Earns Orphan Drug Designation for Autoimmune Hepatitis From the FDA
www_slon_pics / Pixabay

Company Earns Orphan Drug Designation for Autoimmune Hepatitis From the FDA

According to a story from finanznachrichten.de, the Swedish drug company Calliditas Therapeutics has recently announced that the US Food and Drug Administration (FDA) has given one of the company's experimental drugs…

Continue Reading Company Earns Orphan Drug Designation for Autoimmune Hepatitis From the FDA

Potential Gene Therapy for Late Infantile Batten Disease Earns Rare Pediatric Disease Designation

According to a story from BioSpace, the biotechnology company REGENXBIO, Inc. recently announced that its experimental gene therapy candidate called RGX-181 has been granted Rare Pediatric Disease designation from the…

Continue Reading Potential Gene Therapy for Late Infantile Batten Disease Earns Rare Pediatric Disease Designation

This Just In: Patient Reported Experiences are Important for Research in Osteogenesis Imperfecta

What is osteogenesis imperfecta? Osteogenesis imperfecta (OI) actually refers to a group of four distinct rare disorders- OI Type I, II, III, and IV. They're all characterized by brittle bones which…

Continue Reading This Just In: Patient Reported Experiences are Important for Research in Osteogenesis Imperfecta